 |
|
|
| |
IMPAACT 2019: PK & Safety of Dispersible ABC/DTG/3TC in Children with HIV 6 to <14kg
|
| |
| |
CROI 2022 Feb 11-16
Kristina M. Brooks,1 Jennifer J. Kiser,1 Yasha Rani,2 Gaerolwe R. Masheto,3 Faeezah Patel,4 Iris Mustich,5 Barbara Heckman,6 Mark Lojacono,6 Dwight E. Yin,7 Sai Majji,8
Hardik Chandasana,9 Helena Rabie,10 Patricia Flynn,11 on behalf of the IMPAACT 2019 Team
1Deparment of Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO, USA 2Frontier Science & Technology Research Foundation (FSTRF), Brookline, MA, USA 3Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana, USA 4WRHI Shandukani Research Centre, Johannesburg, South Africa 5FHI 360, Durham, NC, USA 6Frontier Science & Technology Research Foundation (FSTRF), Inc., Amherst, NY, USA 7National Institute of Allergy and Infectious Diseases, Rockville, MD, USA 8National Institute of Child Health and Human Development, Bethesda, MD, USA 9GlaxoSmithKline, Collegeville, PA, USA 10University of Stellenbosch, Stellenbosch, South Africa, USA
11St. Jude Children’s Research Hospital, Memphis, TN, USA
|
| |
|
|
|
|
|
